{"id":"https://openalex.org/W2001302736","doi":"https://doi.org/10.1021/jm050394a","title":"Adenosine Kinase Inhibitors. 6. Synthesis, Water Solubility, and Antinociceptive Activity of 5-Phenyl-7-(5-deoxy-\u03b2- d -ribofuranosyl)pyrrolo[2,3-d]pyrimidines Substituted at C4 with Glycinamides and Related Compounds","display_name":"Adenosine Kinase Inhibitors. 6. Synthesis, Water Solubility, and Antinociceptive Activity of 5-Phenyl-7-(5-deoxy-\u03b2- d -ribofuranosyl)pyrrolo[2,3-d]pyrimidines Substituted at C4 with Glycinamides and Related Compounds","alternate_titles":[],"publication_year":2005,"publication_date":"2005-11-03","ids":{"openalex":"https://openalex.org/W2001302736","doi":"https://doi.org/10.1021/jm050394a","mag":"2001302736","pmid":"https://pubmed.ncbi.nlm.nih.gov/16302820"},"language":"en","primary_location":{"id":"doi:10.1021/jm050394a","doi":"https://doi.org/10.1021/jm050394a","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm050394a","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2001302736"],"child_works_count":1,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027863715","display_name":"Brett C. Bookser","orcid":"https://orcid.org/0000-0002-0822-7029","observed_orcids":["https://orcid.org/0000-0002-0822-7029"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Brett C. Bookser","raw_affiliation_strings":["Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108446204","display_name":"Bheemarao G. Ugarkar","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Bheemarao G. Ugarkar","raw_affiliation_strings":["Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000455240","display_name":"Michael C. Matelich","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Michael C. Matelich","raw_affiliation_strings":["Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031882293","display_name":"Robert H. Lemus","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert H. Lemus","raw_affiliation_strings":["Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Matthew Allan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Matthew Allan","raw_affiliation_strings":["Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109403966","display_name":"Megumi Tsuchiya","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Megumi Tsuchiya","raw_affiliation_strings":["Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054039151","display_name":"Masami Nakane","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Masami Nakane","raw_affiliation_strings":["Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045290821","display_name":"Atsushi Nagahisa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Atsushi Nagahisa","raw_affiliation_strings":["Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045414055","display_name":"James B. Wiesner","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"James B. Wiesner","raw_affiliation_strings":["Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5110461190","display_name":"Mark D. Erion","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mark D. Erion","raw_affiliation_strings":["Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Metabasis Therapeutics, Inc., 9390 Towne Centre Drive, San Diego, California 92121, and Pfizer Pharmaceuticals, Central Research, 5-2 Taketoyo, Aichi, Japan 470-23","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5027863715"],"corresponding_institution_ids":["https://openalex.org/I180857899"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":1.2804,"has_fulltext":false,"cited_by_count":67,"citation_normalized_percentile":{"value":0.70721858,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":99},"biblio":{"volume":"48","issue":"24","first_page":"7808","last_page":"7820"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.5713000297546387,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11193","display_name":"Adenosine and Purinergic Signaling","score":0.5713000297546387,"subfield":{"id":"https://openalex.org/subfields/1314","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12827","display_name":"Biochemical and Molecular Research","score":0.2996000051498413,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.04699999839067459,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/adenosine-kinase-inhibitors","display_name":"adenosine kinase inhibitors","score":0.996999979019165},{"id":"https://openalex.org/keywords/pyrrolo-2-3-d-pyrimidine","display_name":"pyrrolo[2,3-d]pyrimidine","score":0.9639999866485596},{"id":"https://openalex.org/keywords/glycinamide","display_name":"glycinamide","score":0.796999990940094},{"id":"https://openalex.org/keywords/water-solubility","display_name":"water solubility","score":0.8740000128746033},{"id":"https://openalex.org/keywords/antinociceptive-activity","display_name":"antinociceptive activity","score":0.9710000157356262},{"id":"https://openalex.org/keywords/oral-analgesia","display_name":"oral analgesia","score":0.5120000243186951}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.9393525123596191},{"id":"https://openalex.org/C155574463","wikidata":"https://www.wikidata.org/wiki/Q170731","display_name":"Solubility","level":2,"score":0.6063696146011353},{"id":"https://openalex.org/C71240020","wikidata":"https://www.wikidata.org/wiki/Q186011","display_name":"Stereochemistry","level":1,"score":0.5611231923103333},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.1723053753376007}],"mesh":[{"descriptor_ui":"D000248","descriptor_name":"Adenosine Kinase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D000700","descriptor_name":"Analgesics","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D000700","descriptor_name":"Analgesics","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000700","descriptor_name":"Analgesics","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001682","descriptor_name":"Biological Availability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002144","descriptor_name":"Callithrix","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004285","descriptor_name":"Dogs","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004355","descriptor_name":"Drug Stability","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D005998","descriptor_name":"Glycine","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008862","descriptor_name":"Microsomes, Liver","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009705","descriptor_name":"Nucleosides","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D009705","descriptor_name":"Nucleosides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D009705","descriptor_name":"Nucleosides","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D010147","descriptor_name":"Pain Measurement","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011741","descriptor_name":"Pyrimidine Nucleosides","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D011741","descriptor_name":"Pyrimidine Nucleosides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D011741","descriptor_name":"Pyrimidine Nucleosides","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D012995","descriptor_name":"Solubility","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014867","descriptor_name":"Water","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D066298","descriptor_name":"In Vitro Techniques","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/jm050394a","doi":"https://doi.org/10.1021/jm050394a","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm050394a","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:16302820","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16302820","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.6240000128746033,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":27,"referenced_works":["https://openalex.org/W1546779238","https://openalex.org/W1653283856","https://openalex.org/W1727768056","https://openalex.org/W1871638289","https://openalex.org/W1950306259","https://openalex.org/W1964399042","https://openalex.org/W1978890358","https://openalex.org/W1980792687","https://openalex.org/W1998825933","https://openalex.org/W2000480344","https://openalex.org/W2001933690","https://openalex.org/W2002503115","https://openalex.org/W2003565414","https://openalex.org/W2031342779","https://openalex.org/W2042104131","https://openalex.org/W2044641074","https://openalex.org/W2068599032","https://openalex.org/W2069506489","https://openalex.org/W2082299271","https://openalex.org/W2088291447","https://openalex.org/W2317601789","https://openalex.org/W2323615511","https://openalex.org/W2497333558","https://openalex.org/W3004755458","https://openalex.org/W3147208818","https://openalex.org/W4235799017","https://openalex.org/W4248107770"],"related_works":["https://openalex.org/W2171430162","https://openalex.org/W2016480458","https://openalex.org/W2032845041","https://openalex.org/W2027828420","https://openalex.org/W1998825933","https://openalex.org/W2002840393","https://openalex.org/W1986781260","https://openalex.org/W2004091091","https://openalex.org/W2026792394","https://openalex.org/W2142676205"],"abstract_inverted_index":{"4-(Phenylamino)-5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine":[0],"1":[1,75],"and":[2,16,66,76,129,139,204,224],"related":[3],"compounds":[4],"known":[5],"as":[6,26,201],"\"diaryltubercidin\"":[7],"analogues":[8],"are":[9,17],"potent":[10],"inhibitors":[11],"of":[12,23,39,57,62,169,197,222],"adenosine":[13],"kinase":[14],"(AK)":[15],"orally":[18],"active":[19],"in":[20,70,104,118,153,162,184,212],"animal":[21],"models":[22],"pain":[24],"such":[25,200],"the":[27,37,54,63,71,89,119,127,163,173,213],"rat":[28,164,214],"formalin":[29,165,215],"paw":[30,166,216],"model":[31,167,217],"(GP3269":[32],"ED50=":[33],"6.4":[34],"mg/kg).":[35,171],"However,":[36,209],"utility":[38],"this":[40,207,228],"compound":[41],"class":[42],"is":[43],"limited":[44],"by":[45,60],"poor":[46],"water":[47,87,106,140],"solubility":[48,82,107,141],"that":[49],"can":[50],"be":[51],"attributed":[52],"to":[53,126,180],"high":[55,220],"energy":[56],"crystallization":[58],"caused":[59],"stacking":[61],"parallel":[64],"C4":[65],"C5":[67],"aryl":[68],"rings":[69],"solid":[72],"state":[73],"(compound":[74],"GP3269":[77],"each":[78],"with":[79,95,124,187,219],"pH":[80,148],"7.4":[81],"<0.05":[83],"microg/mL).":[84],"To":[85],"increase":[86],"solubility,":[88],"hydrophobic":[90],"C4-phenylamino":[91],"substituent":[92],"was":[93,150,178,230],"replaced":[94],"a":[96],"more":[97],"hydrophilic":[98],"group,":[99],"glycinamide.":[100],"This":[101],"modification":[102],"resulted":[103],"improved":[105],"while":[108],"retaining":[109],"AK":[110],"inhibition":[111],"potency.":[112],"Analogues":[113],"were":[114,122],"studied":[115],"where":[116],"changes":[117,125],"glycinamide":[120],"moiety":[121],"combined":[123],"base":[128],"sugar.":[130],"A":[131],"lead":[132],"compound,":[133],"4-N-(N-cyclopropylcarbamoylmethyl)amino-5-phenyl-7-(5-deoxy-beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine":[134],"(16c)":[135],"(IC50=":[136],"3":[137],"nM":[138],"=":[142],"32":[143],"+/-":[144],"9":[145],"microg/mL":[146],"at":[147,191,206],"7.4),":[149],"further":[151,225],"characterized":[152],"biological":[154],"assays.":[155],"Compound":[156],"16c":[157,177],"exhibited":[158],"strong":[159],"oral":[160],"efficacy":[161],"(ED50":[168],"2.5":[170],"In":[172],"most":[174],"advanced":[175],"assay,":[176],"found":[179],"inhibit":[181],"bradykinin-induced":[182],"licking":[183],"marmoset":[185],"monkeys":[186],"an":[188],"ED50":[189],"estimated":[190],"0.9":[192],"mg/kg":[193],"without":[194],"producing":[195],"evidence":[196],"side":[198],"effects":[199],"ataxia,":[202],"sedation,":[203],"emesis":[205],"dose.":[208],"lethal":[210],"toxicity":[211],"occurred":[218],"doses":[221],"16c,":[223],"work":[226],"on":[227],"series":[229],"discontinued.":[231]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2001302736","counts_by_year":[{"year":2026,"cited_by_count":3},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":4},{"year":2015,"cited_by_count":6},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":10},{"year":2012,"cited_by_count":4}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2016-06-24T00:00:00"}
